外泌体miR-200c和miR-141作为原发性中枢神经系统淋巴瘤化疗应答的脑脊液活检生物标志物

核心信息

  • 论文英文标题: Exosomal miR-200c and miR-141 as cerebrospinal fluid biopsy biomarkers for the response to chemotherapy in primary central nervous system lymphoma
  • 期刊: Discov Oncol
  • 发表年份: 2023
  • DOI: 10.1007/s12672-023-00812-1
  • PMID/PMCID: 37971595; PMC10654293

研究概览

To improve early diagnosis and chemotherapy efficacy monitoring in primary central nervous system lymphoma (PCNSL), cerebrospinal fluid (CSF) exosomal microRNA (miRNA) studies were performed. Collectively, miR-200c and miR-141 are likely to be upregulated in CSF exosomes after chemotherapy in patients with PCNSL, highlighting their potential as reliable liquid biopsy biomarkers for PCNSL diagnosis and chemotherapy efficacy monitoring.

核心发现

Exosomal miR-200c and miR-141 levels in CSF from patients with PCNSL were significantly lower than those in control subjects.

The potential target genes of miR-200c and miR-141 in PCNSL included ATP1B3, DYNC1H1, MATR3, NUCKS1, ZNF638, NUDT4, RCN2, GNPDA1, ZBTB38, and DOLK.

研究设计

Small RNA sequencing was performed to identify candidate exosomal miRNAs as CSF biopsy biomarkers from two patients with de novo PCNSL and two patients in remission after chemotherapy.

miR-200c and miR-141 expression in CSF exosomes was further validated using relative quantitative real-time polymerase chain reaction in patients with PCNSL (n = 20), patients with other neurological diseases (n = 10), and normal subjects (n = 10).

Receiver operating characteristic (ROC) curve analyses of miR-200c and miR-141 in the diagnosis and prediction of chemotherapy efficacy in PCNSL were performed in patients treated with methotrexate.

Echo Biotech 角色

脑脊液外泌体分离&电镜/粒径鉴定&miRNA测序&qPCR验证

关联平台: Exoomics®

关联服务与能力: EV Isolation & Purification, EV Basic Characterization (TEM/NTA/WB), EV miRNA Profiling / Sequencing, qPCR Validation

关联产品或试剂: 无明确产品引用

参考文献

原始论文: Exosomal miR-200c and miR-141 as cerebrospinal fluid biopsy biomarkers for the response to chemotherapy in primary central nervous system lymphoma Discov Oncol. 2023. DOI: 10.1007/s12672-023-00812-1. PMID/PMCID: 37971595; PMC10654293.